Product overview

Name Arctigenin
Alternative names (-)-Arctigenin
Purity >98%
Description Potent MAP kinase kinase (MKK/MEK) inhibitor
Write Your Own Review
You're reviewing:Arctigenin
Rate this item:

Biological Data

Biological description Potent MAP kinase kinase (MKK/MEK) inhibitor (IC50 = 1 nM for MKK1/MEK1). Antiviral, anti-cancer, antioxidant and anti-inflammatory compound. Inhibits iNOS expression by suppressing 1-κBα phosphorylation and nuclear translocation of p65 (IC50 = 10 nM). Shows neuroprotective actions.

Solubility & Handling

Storage instructions -20°C (desiccate)
Solubility overview Soluble in ethanol (25mM, gentle warming) or DMSO (100mM)
Important This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.



More Info


More Info

Chemical Data

Purity >98%
Chemical name (3R,4R)-4-[(3,4-Dimethoxyphenyl)methyl]dihydro-3-[(4-hydroxy-3-methoxyphenyl)methyl]-2(3H)-furanone
Molecular Weight 372.42
Chemical structure Arctigenin  [7770-78-7] Chemical Structure
Molecular Formula C21H24O6
CAS Number 7770-78-7
PubChem identifier 64981

References for Arctigenin

References are publications that support the biological activity of the product
  • Arctigenin anti-tumor activity in bladder cancer T24 cell line through induction of cell-cycle arrest and apoptosis.

    Yang S et al (2012) Anat Rec (Hoboken) 295(8) : 1260-6.
  • Arctigenin, a phenylpropanoid dibenzylbutyrolactone lignan, inhibits MAP kinases and AP-1 activation via potent MKK inhibition: the role in TNF-alpha inhibition.

    Cho MK et al (2004) 4(10-11) : 1419-29
  • Arctigenin protects cultured cortical neurons from glutamate-induced neurodegeneration by binding to kainate receptor.

    Jang YP et al (2002) J Neurosci Res 68(2) : 233-40.
  • Potent inhibition of lipopolysaccharide-inducible nitric oxide synthase expression by dibenzylbutyrolactone lignans through inhibition of I-kappaBalpha phosphorylation and of p65 nuclear translocation in macrophages.

    Cho MK et al (2002) Int Immunopharmacol 2(1) : 105-16.

4 Item(s)